TransAct Technologies Secures Major BOHA!
HAMDEN, Conn.--(BUSINESS WIRE)--TransAct ® Technologies Incorporated (Nasdaq: TACT), a global leader delivering software-driven technology and printing solutions, today announced that a leading national convenience store chain has upgraded all of its 1,400 existing BOHA! units to the new BOHA! Terminal 2. The customer, which has been a long-time user of the original BOHA! Terminal, had approved an upgrade to the BOHA! Terminal 2 across its entire store network. The rollout to all locations was successfully completed during Q1 2025.
The BOHA! Terminal 2 helps store teams boost productivity and efficiency — a critical advantage in today's labor-constrained environment. By streamlining key foodservice workflows, it enables employees to complete tasks faster, with greater accuracy and reliability, leading to measurable labor savings, improved food safety, and reduced food waste. For multi-unit operators, these improvements scale into significant operational and financial impact.
'We are proud to partner with this leading convenience store operator as they modernize their foodservice operations with the BOHA! Terminal 2,' said John Dillon, CEO of TransAct Technologies. 'This full-fleet upgrade, with many locations receiving 2 devices, is a strong endorsement of the value our technology delivers every day. It demonstrates that BOHA! is not only reliable at scale but also a proven driver of ROI, operational excellence, and food safety. We are thrilled to support this next phase of their digital transformation.'
The customer also operates a variety of national brand restaurants within their convenience store locations. TransAct's BOHA! solutions play a critical role in keeping these restaurant operations running smoothly, ensuring consistent food safety processes and operational efficiency across all their brands.
This latest upgrade further highlights the value of TransAct's BOHA! ecosystem in helping customers optimize performance, simplify compliance, and achieve operational excellence in convenience store foodservice operations.
Customers and prospects can explore the BOHA! Terminal 2 and the rest of the BOHA! Platform at the National Restaurant Association Show from May 17-20, 2025. Visit TransAct at booth 7250 to see them in action! You may also visit www.transact-tech.com.
About TransAct Technologies Incorporated
TransAct Technologies Incorporated is a global leader in developing and selling software-driven technology and printing solutions for high-growth markets including food service, casino and gaming, and POS automation. The Company's solutions are designed from the ground up based on customer requirements and are sold under the BOHA! ®, AccuDate ®, EPICENTRAL ®, Epic and Ithaca ® brands. TransAct has sold over 3.9 million printers, terminals and other hardware devices around the world and is committed to providing world-class service, spare parts, and accessories to support its installed product base. Through the TransAct Services Group, the Company also provides customers with a complete range of supplies and consumable items both online at http://www.transactsupplies.com and through its direct sales team. TransAct is headquartered in Hamden, CT. For more information, please visit http://www.transact-tech.com or call (203) 859-6800.
©2025 TRANSACT Technologies Incorporated. All rights reserved. TransAct ®, BOHA! ®, AccuDate ®, Epic Edge ®, EPICENTRAL ® and Ithaca ® are trademarks of TransAct Technologies Incorporated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
34 minutes ago
- Business Insider
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.
Yahoo
38 minutes ago
- Yahoo
NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion
NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 AI Stocks on Wall Street's Radar. One of the most notable analyst calls on Tuesday, June 10, was for NVIDIA Corporation (NASDAQ:NVDA). Bank of America reiterated the stock as 'Buy,' stating that data center demand trends remain robust for Nvidia. 'Developing AI infrastructure leveraging local datasets and workforces is a rapidly growing global phenomenon and we expect it to contribute $50bn+ annually or 10%+ of long-term AI addressable market.' A powerful aerial view of the company's data center, exemplifying the digital services and informatics being offered. In other latest news, Nvidia Corporation and Hewlett-Packard Enterprise said on Tuesday that they are partnering with the Leibniz Supercomputing Centre to build a new supercomputer using Nvidia's next-generation chips. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
